Abstract
e16345 Background: Pancreatoblastoma (PB) is a rare tumor originating from pancreatic epithelial exocrine cells with a very poor prognosis. At diagnosis, it often presents with large lesions encompassing overlapping regions and may involve the entire pancreas. PB is frequently associated with distant metastasis and often occurs in children under the age of 10. An optimal treatment strategy has yet to be established. Analyzing trends in diagnoses may yield valuable information about its epidemiology. The National Cancer Database (NCDB) was utilized to uncover the demographic factors in patients diagnosed with PB. Methods: A retrospective cohort study from 2004 to 2020 was conducted using the NCDB. 82 patients were found with a histologically confirmed diagnosis of PB (ICD-8971-3). Race, gender, Hispanic origin, type of treatment facility, insurance coverage, and distance from patient residence to treatment facility were analyzed via descriptive statistics. Trends in incidence were interpreted using regression analysis. Results: A total of 82 individuals in the NCDB were confirmed to be diagnosed with pancreatoblastoma between 2004-2020. The incidence rate of patients diagnosed per year is steady (R² =0.0). The average age of diagnosis was 55.3 years (SD = 15.4, range = 19-90) with women (89%) being more likely to be diagnosed compared to men (11%). None of the observed patients utilized palliative care, and from this population, 87% received surgery, and 28% received chemotherapy as their primary treatment. The majority of the patients were non-Hispanic (89%) and White (87%). Most patients were privately insured (52%) and lived in metropolitan areas with a population greater than 1 million (51%). More patients were in the highest quartile of income earners (33%), compared to those in the second, third, or fourth quartiles. Fewer patients were treated at a comprehensive community cancer program (28%) than in an academic/research program (37%). Most patients (79%) had a Charlson/Deyo comorbidity scores of 0 and were applicable to Stage I group (49%). Conclusions: This represents the first analysis of pancreatoblastoma within the NCDB to our knowledge, addressing a notable knowledge gap. Pancreatoblastoma is predominantly treated by surgery, consistent with previous case reports. Notably, our study pioneers the exploration of socioeconomic aspects among pancreatoblastoma patients. Findings reveal a higher likelihood of these patients belonging to the highest income quartile, residing in densely populated metropolitan areas, and receiving treatment within academic/research programs. Further investigation is warranted to comprehend the influence of demographic and socioeconomic variables on the diagnosis, treatment approaches, and overall survival of individuals with pancreatoblastoma.